



NUCLEA
BIOTECHNOLOGIES

PRESS RELEASE

For Immediate Release:
January 3, 2012

Contact: Patrick J. Muraca
Office: 413.749.4705

Nuclea Biotechnologies Receives U.S. Patent 8,088,589 B2 for EGFR Inhibitor Assay

Pittsfield, MA -- Biomarker pioneer Nuclea Biotechnologies, Inc. today announced the United States Patent and Trademark Office has issued patent number 8,088,589 B2 covering a gene/protein signature for predicting the therapeutic efficacy of EGFR inhibitors in lung cancer patients.

The invention relates to an assay for determining if a patient afflicted with lung cancer is likely to respond to treatment with a therapeutic agent that inhibits EGFR, such as gefitinib (IRESSA[®]) or erlotinib (TARCEVA[®]). Lung cancer is a condition where early detection and early effective treatment are key to survival. Nuclea's assay provides clinicians with a valuable tool for determining and monitoring the efficacy of treatment with an EGFR inhibitor, and benefits lung cancer patients by identifying the subpopulation of patients that would derive the most benefit from these agents, as well as those patients that would benefit from a different therapeutic treatment.

This is the ninth patent for Nuclea, which discovers and develops biomarkers and diagnostic assays that can help predict the stage or aggressiveness of certain cancers, as well as which treatments will be effective for certain patients, depending on their genetic makeup.

"This is another major step forward for Nuclea and the future of personalized medicine," said Patrick J. Muraca, president & CEO of Nuclea Biotechnologies, Inc. "Our continued research in this field will lead to more comprehensive detection and more effective treatment of lung cancer and other deadly diseases."

Nuclea Biotechnologies, Inc. is headquartered in Pittsfield, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories ("NDL") which has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers ("NBM") which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics ("NBT") which develops novel therapeutics.